Clinical Trials Logo

Alzheimer Disease (AD) clinical trials

View clinical trials related to Alzheimer Disease (AD).

Filter by:
  • None
  • Page 1

NCT ID: NCT05395624 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Start date: February 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

NCT ID: NCT04566003 Completed - Clinical trials for Alzheimer Disease (AD)

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Start date: October 26, 2020
Phase: Phase 1
Study type: Interventional

The study aims to compare tau targeted radiotracers [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).

NCT ID: NCT04055532 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Biomarkers in Neurodegenerative Diseases

Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

NCT ID: NCT03518073 Completed - Clinical trials for Alzheimer Disease (AD)

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

Start date: April 30, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

NCT ID: NCT03030586 Recruiting - Clinical trials for Frontotemporal Lobar Degeneration

ADDIA Proof-of-Performance Clinical Study

ADDIA
Start date: September 1, 2016
Phase:
Study type: Observational

The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD). ADDIA clinical study is a multi-centre, non-interventional, prospective, proof-of-performance study with only one visit. About 800 well-characterized subjects will be recruited into 3 groups in 2:1:1 ratio, namely patients with Alzheimer's disease (AD), patients with non-AD neurodegenerative disease (NAD) and 200 control subjects (healthy as compared to their age). - 400 patients with Alzheimer's disease (AD): 200 patients with mild AD, 200 patients with moderate-to-severe AD, - 200 patients with non-Alzheimer's neurodegenerative diseases (NAD), - 200 controls (healthy as compared to their age).